We are using cookies to give you the best experience on our site. Cookies are files stored in your browser and are used by most websites to help personalise your web experience.

By continuing to use our website without changing the settings, you are agreeing to our use of cookies.

Find out more
For more information, go to

Smoking 'can reduce effectiveness of psoriatic arthritis treatments'

Published on 30 July 2014
Smoking 'can reduce effectiveness of psoriatic arthritis treatments'

People who smoke could be reducing their own chance of being successfully treated for psoriatic arthritis, according to a new study from Denmark.

The research, led by scientists at Gentofte Hospital in Copenhagen, aimed to investigate the association between tobacco smoking and disease activity, treatment adherence and therapy responses among patients with psoriatic arthritis who were receiving anti-TNF treatments.

Drawing data from the Danish nationwide DANBIO registry, the team analysed information pertaining to 1,388 psoriatic arthritis sufferers, looking at their smoking habits and their successes with treatment, while also taking into account factors such as gender and therapy type.

According to results published in the Annals of the Rheumatic Diseases, of the 1,148 patients whose smoking status was known, 33 per cent of the people were current smokers, 26 per cent had done so previously and 41 per cent had never taken up the habit.

It was revealed that patients who were still smoking tended to have worse reported outcomes at the start of the study, as well as being less likely to successfully adhere to anti-TNF treatment once it began. Moreover, they were likelier to have a poor response to therapy after six months.

This effect was shown to be more pronounced among men than women, with treatment adherence taking a greater hit among those receiving the drugs infliximab or etanercept rather than adalimumab.

Anti-TNF therapies are an important class of arthritis therapies that have revolutionised treatment for various inflammatory conditions since being pioneered and developed by Arthritis Research UK. Clinicians are likely to be keen to explore all available options to maximise their effectiveness.
A spokesman for Arthritis Research UK commented: "Previous research has shown that people with rheumatoid arthritis have a poorer response to anti-TNF therapy than non-smokers, as well as the habit being a risk factor for developing the disease in the first place, so these similar findings in psoriatic arthritis are not particularly surprising. It provides further evidence of the widespread harm of smoking."

For more information, go to
Arthritis Research UK fund research into the cause, treatment and cure of arthritis. You can support Arthritis Research UK by volunteering, donating or visiting our shops.